Table: Daito - 9-MTH group results
Apr 14 (Reuters)-
Daito Pharamaceutical Co Ltd
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
9 months ended 9 months ended Year to
Feb 28, 2017 Feb 29, 2016 May 31, 2017
LATEST YEAR-AGO LATEST
RESULTS RESULTS FORECAST
Sales 27.92 27.01 38.10
(+3.4 pct) (+9.6 pct) (+4.8 pct)
Operating 3.08 2.75 3.70
(+11.9 pct) (+14.8 pct) (+4.1 pct)
Recurring 3.04 2.86 3.75
(+6.4 pct) (+21.0 pct) (+1.0 pct)
Net 2.04 1.91 2.60
(+6.9 pct) (+25.9 pct) (+1.3 pct)
EPS 163.30 yen 152.74 yen 207.76 yen
Ann Div 30.00 yen 33.00 yen
-Q2 div 15.00 yen 15.00 yen
-Q4 div 15.00 yen 18.00 yen
NOTE - Daito Pharamaceutical Co Ltd.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4577.T
((Tokyo Headline News Desk +813 6441 1812))
Recent news on Daito Pharmaceutical
See all newsTo Buy Back Up To 4.4% Of Own Shares Worth 2 Billion Yen
Table: Daito Pharmaceutical -Q1 group results
Execution Of JV And Share Transfer Agreement For Transfer Of Kyorin Pharmaceutical's Generic Drug Business To JV By Daito, Meiji Seika Pharma And Dbj
Table: Daito -2025/26 parent results
Table: Daito -2025/26 group results